Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in Bioverativ Inc (NASDAQ:BIVV) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 15,778 shares of the biotechnology company’s stock, valued at approximately $900,000.

Several other institutional investors have also bought and sold shares of the stock. Advisors Asset Management Inc. purchased a new stake in Bioverativ during the third quarter worth $137,000. TCI Wealth Advisors Inc. purchased a new stake in Bioverativ during the third quarter worth $186,000. Canada Pension Plan Investment Board purchased a new stake in Bioverativ during the third quarter worth $194,000. ACG Wealth purchased a new stake in Bioverativ during the third quarter worth $205,000. Finally, Roberts Glore & Co. Inc. IL purchased a new stake in Bioverativ during the third quarter worth $232,000. Hedge funds and other institutional investors own 95.23% of the company’s stock.

A number of analysts have commented on BIVV shares. Jefferies Group reiterated a “buy” rating and set a $70.00 target price (up from $67.00) on shares of Bioverativ in a research report on Wednesday, August 9th. Zacks Investment Research downgraded Bioverativ from a “strong-buy” rating to a “sell” rating in a research report on Wednesday, August 9th. Evercore ISI started coverage on Bioverativ in a research report on Wednesday, August 16th. They set an “in-line” rating and a $58.00 target price on the stock. Royal Bank Of Canada started coverage on Bioverativ in a research report on Thursday, September 14th. They set a “sector perform” rating and a $59.00 target price on the stock. Finally, Argus upgraded Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 target price on the stock in a research report on Wednesday, September 20th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $60.93.

Shares of Bioverativ Inc (NASDAQ BIVV) opened at $50.68 on Thursday. Bioverativ Inc has a 12-month low of $40.00 and a 12-month high of $64.41.

Bioverativ (NASDAQ:BIVV) last issued its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.25. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The business had revenue of $291.60 million for the quarter, compared to the consensus estimate of $285.45 million. Bioverativ’s quarterly revenue was up 27.2% compared to the same quarter last year. research analysts forecast that Bioverativ Inc will post 2.45 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/commonwealth-of-pennsylvania-public-school-empls-retrmt-sys-invests-900000-in-bioverativ-inc-bivv/1748713.html.

About Bioverativ

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).

Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.